2002
DOI: 10.1183/09031936.00.02622001
|View full text |Cite
|
Sign up to set email alerts
|

Assisted ventilation for heart failure patients with Cheyne-Stokes respiration

Abstract: Patients with chronic congestive cardiac failure (CCF) frequently suffer from central sleep apnoea syndrome (CSAS). Continuous positive airway pressure (CPAP) has been suggested as a treatment. The authors hypothesised that bilevel ventilation might be easier to initiate and superior to CPAP at correcting the sleeprelated abnormality of breathing in patients with CCF.After excluding those with a history suggestive of obstructive sleep apnoea, 35 patients with CCF (left ventricular ejection fraction v35%) were … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
64
1
3

Year Published

2007
2007
2022
2022

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 97 publications
(69 citation statements)
references
References 30 publications
(34 reference statements)
1
64
1
3
Order By: Relevance
“…Thus, therapeutic options have varied markedly from positive airway pressure (PAP) devices, including continuous positive airway pressure (CPAP), [2][3][4][5][6] bilevel positive airway pressure therapy (BPAP), [7][8][9] and adaptive servoventilation, [10][11][12][13]20 to supplemental O 2 , 14-17 carbon dioxide, 21,22 and/or pharmacologic agents. [23][24][25]29,30 The outcomes of therapy have also varied considerably, with limited evidence to establish the effectiveness of any therapy for CSA. [26][27][28][29]31,32 The majority of published literature has focused on the treatment of CSA secondary to congestive heart failure (CHF), [2][3][4][5][6][7][8][9][10][11][15][16][17][18][19][20][21][22][26][27][28]…”
mentioning
confidence: 99%
“…Thus, therapeutic options have varied markedly from positive airway pressure (PAP) devices, including continuous positive airway pressure (CPAP), [2][3][4][5][6] bilevel positive airway pressure therapy (BPAP), [7][8][9] and adaptive servoventilation, [10][11][12][13]20 to supplemental O 2 , 14-17 carbon dioxide, 21,22 and/or pharmacologic agents. [23][24][25]29,30 The outcomes of therapy have also varied considerably, with limited evidence to establish the effectiveness of any therapy for CSA. [26][27][28][29]31,32 The majority of published literature has focused on the treatment of CSA secondary to congestive heart failure (CHF), [2][3][4][5][6][7][8][9][10][11][15][16][17][18][19][20][21][22][26][27][28]…”
mentioning
confidence: 99%
“…Its effects are also maintained during the day as observed in the LV EF improvement 2,11,12 , in the NYHA classification of CHF 2,9,11,12 , in the reduction of diurnal somnolence at the Epworth scale and decreased heart frequency during the state of wakefulness 11 . It also decreases the sympathetic activity by reducing the concentrations of nocturnal urinary norepinephrine and morning plasma norepinephrine 2 and decreases the frequency of ventricular arrhythmias 10 .…”
Section: Cpapmentioning
confidence: 90%
“…The non-responders had a mean AHI of 62 and the responders, a mean AHI of 36, which shows that more severe patients may not respond to CPAP, probably due to the fact that the latter can lead to a tendency to wake up, promoting respiratory instability due to the more elevated pressures used in these patients. Other studies have found a higher frequency of responders, but they had less severe cohorts 9 .…”
Section: Cpapmentioning
confidence: 99%
See 2 more Smart Citations